Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Are the Latest Market Insights for the Brain Tumor Drugs Industry?

The market for ranibizumab has seen consistent growth over the past several years. Projections show an enlargement from $2.66 billion in 2024 to $2.76 billion in 2025, indicating a compound annual growth rate (CAGR) of 3.6%. This growth during the historical period can be credited to the diversification of clinical trials within burgeoning markets, an increase in age-related macular degeneration (AMD) cases, heightened awareness about diseases impacting the retina, the high prevalence of diabetic retinopathy, governmental initiatives and funding, as well as rising expenditure in healthcare.

The market for ranibizumab is projected to experience consistent expansion in the coming years, culminating in ” $3.2 billion in 2029 with a compound annual growth rate (CAGR) of 3.8%. The anticipated upturn during this forecast period is due to factors such as continued research and development, newly introduced biosimilars, escalating focus on combination treatments, the emergence of teleophthalmology, widening applications for ranibizumab, and accommodating reimbursement practices. Major forecast period trends encompass developments in biotechnology, technological progress in drug delivery systems, a shift towards individualized healthcare, increased application of artificial intelligence in ophthalmology, the formulation of longer-lasting solutions, and the growth of patient-focused care models.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=16172&type=smp

What Forces Are Driving The Growth Of The Brain Tumor Drugs Industry?

One of the main catalysts propelling the brain tumor drugs market’s growth is the escalating occurrence of Neurological Disorders across the globe. These disorders are amongst the most common, due to factors like extended life expectancy, higher exposure to infections, and inactive lifestyles. For instance, according to the National Brain Tumor Society, approximately 700,000 individuals in the United States are living with a primary brain tumor and about 86,000 new diagnoses are expected. The surge in patients diagnosed with neurological disorders, including brain tumors, is escalating the demand for drugs used in treatment and consequently, driving the growth of the brain tumor drugs market.

The ranibizumab market covered in this report is segmented –

1) By Product: Single Use Prefilled Syringe, Single Use Glass Vial

2) By Application: Wet Age Related Macular Degeneration (AMD), Diabetic Retinopathy (DR), Diabetic Macular Edema (DME), Myopic Choroidal Neovascularization (MCNV), Retinal Vein Occlusion (RVO)

3) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Other Distribution Channels

Subsegments:

1) By Single Use Prefilled Syringe: 0.3 Ml Syringe, 0.5 Ml Syringe, 1 Ml Syringe, Other Volume Variants

2) By Single Use Glass Vial: 0.5 Mg Or 0.05 Ml Vial, 1.0 Mg Or 0.1 Ml Vial, 2.0 Mg Or 0.2 Ml Vial, Other Volume Variants

What Future Market Trends Are Projected For The Brain Tumor Drugs Industry?

Large businesses in the ranibizumab market are shifting their focus towards more affordable treatments such as ranibizumab biosimilars, aimed at treating and preventing vision loss due to retinal disorders. A ranibizumab biosimilar is a biologic drug that is essentially the same as the original ranibizumab but sold under a different brand name. These versions maintain similar safety and effectivity but are offered at a lower cost. For example, in April 2024, the German biotech company, Formycon AG, and the Swiss biopharmaceutical firm, Bioeq AG, launched FYB201, a biosimilar of Lucentis (Ranibizumab), in Canada and Switzerland. This was made possible by obtaining marketing authorization from Health Canada under the brand name Ranopto and Swissmedic under the brand Ranivisio. FYB201 emerges as a new, quality, effective and economically priced treatment for individuals stricken with severe retinal diseases. Already, it has proven to be a cost-saving treatment option for patients in the USA and various European regions.

Who Are The Primary Players Operating Across The Global Brain Tumor Drugs Market?

Major companies operating in the ranibizumab market are F. Hoffmann-La Roche AG, Bayer AG, Novartis AG, Teva Pharmaceutical Industries Ltd, Regeneron Pharmaceuticals Inc., Biogen Inc, Sun Pharmaceutical Industries Ltd., Stada Arzneimittel AG, Genentech Inc., Dr Reddy’s Laboratories Ltd, Cipla Limited, Samsung Biologics Co Ltd, Lupin Limited, Biocon Limited, Celltrion Healthcare Co Ltd, Glenmark Pharmaceuticals Limited, Enzene Biosciences Ltd, Coherus BioSciences Inc, Amman Pharmaceutical Industries, Formycon AG, Intas Pharmaceuticals Ltd, Alvotech, Xbrane Biopharma AB

https://www.thebusinessresearchcompany.com/report/ranibizumab-global-market-report

Which Region Offers The Most Growth Potential For The Brain Tumor Drugs Market Through 2029?

North America was the largest region in the ranibizumab market in 2024. The regions covered in the ranibizumab market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=16172&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model